GET DAILY SIGNALSSRX Global (SRXH) Declines -27% Over 30 Days, Remains Below Net Asset Value
Key Takeaways
- SRX Global (SRXH) shares fell roughly 27% over the trailing 30 days, sliding from about $1.29 to around $0.94.
- The decline extends a broader downtrend, with the stock down close to 49% over the trailing three months following July's post-consolidation volatility.
- The share price remains well below the company's reported preliminary net asset value of about $3.07 per share as of June 30, 2026.
- Sentiment has been pressured by convertible-preferred capital raises, a shrinking cash position disclosed in the latest balance-sheet update, and a wide gap between the share price and stated book value.
- Corporate activity continued during the period, including a CERo Therapeutics acquisition agreement, AI-powered ETF plans, and an active share-repurchase program.
Company Overview: SRX Global (SRXH) Focus and Holdings
SRX Global Inc. (NYSE American: SRXH) is a North Palm Beach, Florida-based, AI-driven platform focused on generating long-term shareholder value through investments in high-conviction operating companies, strategic assets, and technology-enabled opportunities. Formerly known as SRx Health Solutions, the company completed the acquisition of EMJX, an AI-enabled digital-asset treasury platform, and a 1-for-60 reverse stock split in July 2026.
The company's portfolio spans multiple sectors. It owns the Halo pet-wellness brand, holds a stake in Vistagen Therapeutics (VTGN), and has agreements to acquire cellular immunotherapy developer CERo Therapeutics (CERO). Management has also committed capital toward AI-powered exchange-traded funds and a multi-strategy trading platform built on the EMJX system. Investors follow the stock closely because it trades at a substantial discount to its reported net asset value and because its strategy combines cash-rich treasury management with opportunistic, technology-driven investments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
SRXH Stock Performance Over the Past Month and Quarter
Over the last 30 days, SRXH declined approximately 27%, moving from a closing price near $1.29 in mid-October to roughly $0.94. The move was largely one-directional, with intermittent bounces that failed to hold, reflecting persistent selling pressure rather than a single sharp event.
The longer trend is steeper. Compared with a level near $1.83 in mid-August, the stock is down close to 49% over the trailing three months. After spiking in early-to-mid July following the EMJX acquisition and reverse split, the shares normalized lower through August and September and continued to drift downward into November. This pattern indicates that the post-consolidation repricing, rather than one discrete catalyst, has been the dominant force shaping the stock's trajectory.
Key Drivers Behind the Recent Price Movement
The most consequential update during the period came on October 30, when the company disclosed roughly $34 million in aggregate cash, cash equivalents, restricted cash, and short-term U.S. Treasury bills, and confirmed it held no cryptocurrency exposure. That figure was below the approximately $55 million in cash and short-term investments the company had reported as of June 30, and it drew renewed attention to the gap between the share price and the previously stated preliminary net asset value of about $3.07 per share.
At the same time, the company reiterated that it was actively using its stock-repurchase program, which permits repurchases of up to the lesser of 10 million shares or 50% of shares outstanding for up to $20 million through July 7, 2027. Earlier financing activity also weighed on sentiment: in late August the company sold 3,579 shares of Series C convertible preferred stock for approximately $2.825 million, securities that are convertible into common equity. For a micro-cap name, the combination of convertible issuance, a declining cash balance, and a persistent discount to book value has kept pressure on the share price.
Quarterly Trends and Corporate Developments
Over the trailing three months, the stock's decline has been shaped by a post-reverse-split normalization coupled with ongoing corporate transformation. Following July's consolidation, management issued a one-time cash dividend of $0.05 per share and authorized a substantial buyback, while also extending financing to CERo Therapeutics and ultimately signing an agreement to acquire the company. In October, SRX Global committed $1.5 million to launch a family of AI-powered ETFs with Kupa AI and $2.5 million to a multi-strategy trading platform with 5T Trading, powered by the EMJX system.
Despite this activity, the shares continued to fall. Market participants have focused on dilution from convertible preferred securities, the drawdown in the cash balance disclosed in the October update, and the removal of cryptocurrency from the balance sheet. The result has been a widening discount between the market price and the company's stated net asset value, a dynamic that has defined the quarter's price action.
Looking Ahead: Upcoming Catalysts for SRXH
Several factors are likely to shape the stock's direction in the months ahead. The company has said it expects to report fiscal year-end results and file its Annual Report on Form 10-K in early December, which should clarify the number of shares repurchased, the average price paid, and the full financial picture. Investors will also monitor progress on the CERo Therapeutics acquisition and the Phase 1 CERTAIN-T trial of CER-1236, for which the University of California, Davis was activated as a clinical site.
Broader themes remain relevant as well. The rollout of the EMJX platform and the planned AI-powered ETFs will test whether the company's technology-driven strategy can translate into measurable value. Meanwhile, macro conditions, digital-asset market sentiment, small-cap liquidity, and any further capital-raising activity will continue to influence the shares. As always, these considerations are informational and do not constitute a forecast of future performance. From what I see, checking Tickeron’s AI Trend Prediction Engine can provide additional context on potential movements.
Exploring AI Tools in My Research Process
In my own analysis, I often turn to Tickeron’s AI Trading Bots to help evaluate automated strategies across a range of tickers. The platform features hundreds of bots with different approaches and timeframes, making it straightforward to compare options that align with varying risk levels. This adds a useful layer when reviewing names like SRXH alongside traditional research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
SRXH's RSI Indicator climbs out of oversold territory
The RSI Indicator for SRXH moved out of oversold territory on November 10, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 43 similar instances when the indicator left oversold territory. In 42 of the 43 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 62 of 68 cases where SRXH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for SRXH just turned positive on November 10, 2026. Looking at past instances where SRXH's MACD turned positive, the stock continued to rise in 36 of 39 cases over the following month. The odds of a continued upward trend are 90%.
Following a +8.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRXH advanced for three days, in 196 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
SRXH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRXH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for SRXH entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.115) is normal, around the industry mean (6.914). P/E Ratio (-0.042) is within average values for comparable stocks, (7.137). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.458). SRXH's Dividend Yield (0.246) is considerably higher than the industry average of (0.049). P/S Ratio (0.338) is also within normal values, averaging (5.003).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. SRXH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRXH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
From Analysis to Action: AI Trading Bots Redefining Hedge Fund Operations
Mastercard (MA) Stock Analysis: Performance, Earnings, Dividends, and Market Trends as of May 28, 2025
What Is Spread Betting and How Does It Work in Finance?
Top Stocks in Online Retail and Digital Media
Rising Foods: Top Stocks to Watch
General Information
Industry FoodMajorDiversified
Advertisement